Information Provided By:
Fly News Breaks for October 8, 2018
MZOR, MDT
Oct 8, 2018 | 08:31 EDT
Argus analyst David Toung raised his price target on Medtronic (MDT) to $120 and kept his Buy rating, saying the company's earnings should benefit "significantly" from the expansion of its spine business that carries some of its highest margins. As such, the analyst is positive on Medtronic's acquisition of Mazor Robotics (MZOR) and the launch of new products, while also pointing to the company's "solid growth" in its Brain Therapies and Pain Therapies units and from its Diabetes Group. Toung further cites Medtronic's attractive valuation of 18.8-times his expected FY19 earnings, which is below the 19.9-times peer group average multiple of his covered med-tech stocks.